Shuichi Midorikawa

Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.

M. Ogura, K. Tobinai, K. Ishizawa, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.

M. Ogura, A. Utsunomiya, K. Tobinai, 2016, The Lancet. Haematology.

Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study

M. Taniwaki, S. Iida, T. Uchida, 2016, Cancer science.

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

H. Iwasaki, S. Iida, K. Tobinai, 2015, Cancer science.

Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma

M. Ogura, K. Tobinai, K. Ishizawa, 2015 .

Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma

K. Izutsu, K. Tobinai, P. Fustier, 2019, International Journal of Hematology.

Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan

J. Kuroda, Tomoki Ito, Daisuke Ichikawa, 2023, PloS one.